GHK-Cu: clinical evidence record
Also known as: Copper Tripeptide-1, Glycyl-L-Histidyl-L-Lysine Copper, Prezatide
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · GHK-Cu
Discovered by Loren Pickart in 1973. Endogenous in human plasma, declining with age. Extensive cosmetic and wound-healing literature, with limited human RCT-grade efficacy work outside topical formulations. Injectable form is research-tier.
Mechanism of action
How GHK-Cu works
Naturally occurring tripeptide (Glycyl-L-Histidyl-L-Lysine) that complexes copper ions with high affinity. Proposed to modulate gene expression linked to extracellular matrix synthesis, antioxidant signalling, and wound-healing pathways in preclinical and in-vitro models.
Top peer-reviewed citations
Selection of the most-cited peer-reviewed literature on GHK-Cu. Where a verified PMID or DOI is shown, the citation links to the original record. Other citations list the title, authors, journal and year so the reader can locate the paper through the journal index or the PubMed search linked below. PeptideClear publishes editorial commentary, not clinical guidance.
-
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A. BioMed Research International, 2015.
-
The human tripeptide GHK-Cu in prevention of oxidative stress
Pickart L, Vasquez-Soltero JM, Margolina A. Oxidative Medicine and Cellular Longevity, 2012.
-
Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver
Pickart L, Thaler MM. Nature New Biology, 1973.
-
GHK and DNA: resetting the human genome to health
Pickart L, Vasquez-Soltero JM, Margolina A. BioMed Research International, 2014.
-
Tripeptide-copper complex stimulation of dermal fibroblast collagen synthesis
Maquart FX, Pickart L, Laurent M, et al.. FEBS Letters, 1988.
-
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A. International journal of molecular sciences, 2018.
-
Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways
Ma WH, Li M, Ma HF, et al.. Life sciences, 2020.
-
The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice
Park JR, Lee H, Kim SI, et al.. Oncotarget, 2016.
-
Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts
Gruchlik A, Jurzak M, Chodurek E, et al.. Acta poloniae pharmaceutica, 2012.
-
Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?
Ogórek K, Nowak K, Wadych E, et al.. Molecules (Basel, Switzerland), 2025.
Full PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=GHK-Cu+copper+tripeptide.
UK regulatory status
Plain-English summary of where GHK-Cu sits under the four UK and international frameworks that govern peptide supply. Editorial commentary, not legal advice.
- Misuse of Drugs Act 1971: Not controlled under the Misuse of Drugs Act 1971.
- Psychoactive Substances Act 2016: Not scheduled under the Psychoactive Substances Act 2016.
- MHRA medicines classification: No UK marketing authorisation as a medicine.
- WADA Prohibited List: Not currently listed on the WADA Prohibited List.
Full regulatory record: GHK-Cu UK regulatory status.
Risks and unknowns
What the literature does not yet show about GHK-Cu
Known concerns
- Most published efficacy claims for GHK-Cu require careful interpretation. Read the cited papers in full before drawing conclusions.
- Purity of UK research-peptide supply varies between retailers. Certificates of analysis and HPLC documentation differ.
- Cold-chain handling between manufacture and delivery is not standardised across the research-peptide market.
- Independent replication of single-group findings is the key check on any preclinical claim.
Open questions in the literature
- Where human pharmacokinetics have not been formally characterised, dose translation from animal models is not reliable.
- Long-term safety profile beyond the duration of published studies remains an open question.
- Interactions with other prescribed or unlicensed substances are typically not studied.
Regulatory note
No UK marketing authorisation as a medicine. Not currently listed on the WADA Prohibited List. The moment a UK seller or commentator makes a therapeutic claim, MHRA can treat the product as an unlicensed medicinal product.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Related reading on PeptideClear
Frequently asked questions
What is the evidence level for GHK-Cu?
What is the UK regulatory status of GHK-Cu?
Has GHK-Cu been tested in human clinical trials?
Where can I read the source literature for GHK-Cu?
Last verified 2026-05-22. Editorial commentary, not legal or clinical advice. Citations without a linked identifier can be located through the PubMed search and the journal index.